Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$133.09

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $121.17 2
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Myriad Genetic Laboratories, Inc. $106.53 1
Novo Nordisk Inc $14.64 1
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $133.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $14.6412/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811377771 CMS
Myriad Genetic Laboratories, Inc. $106.5312/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834546673 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845870475 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

185 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $239.75 12/31/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991128215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $301.89 12/31/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991129889
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,323.77 12/31/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991132351
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,838.25 12/31/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991132545
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,197.80 12/31/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991136643
Principal investigator 1 AstraZeneca Pharmaceuticals LP $396.03 12/31/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991138511
Principal investigator 1 Genentech, Inc. $34,342.00 12/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040609759
Principal investigator 1 Seagen Inc. $988.00 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887185
Principal investigator 1 Seagen Inc. $49.70 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887199
Principal investigator 1 Seagen Inc. $29.40 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887213
Principal investigator 1 Seagen Inc. $1,389.00 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887241
Principal investigator 1 Seagen Inc. $49.70 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887359
Principal investigator 1 Seagen Inc. $29.40 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887371
Principal investigator 1 Genentech, Inc. $198.00 12/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040610393
Principal investigator 1 Seagen Inc. $1,389.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885847
Principal investigator 1 Seagen Inc. $988.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885875
Principal investigator 1 Seagen Inc. $49.70 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885889
Principal investigator 1 Seagen Inc. $29.40 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885903
Principal investigator 1 Seagen Inc. $460.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885919
Principal investigator 1 Seagen Inc. $164.50 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887131
Principal investigator 1 Seagen Inc. $295.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995887143
Principal investigator 1 Seagen Inc. $217.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887157
Principal investigator 1 Seagen Inc. $280.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887171
Principal investigator 1 Seagen Inc. $988.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887287
Principal investigator 1 Seagen Inc. $217.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887301
Principal investigator 1 Seagen Inc. $295.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995887315
Principal investigator 1 Seagen Inc. $217.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887329
Principal investigator 1 Seagen Inc. $1,389.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995887345
Principal investigator 1 Genentech, Inc. $1,350.00 11/01/2023 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1040616989
Principal investigator 1 Genentech, Inc. $1,500.00 10/18/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040609161
Principal investigator 1 Seagen Inc. $956.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885817
Principal investigator 1 Seagen Inc. $765.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885833
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 10/10/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173365
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 10/10/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173379
Principal investigator 1 Genentech, Inc. $9,000.00 10/04/2023 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1040616619
Principal investigator 1 Novartis Pharmaceuticals Corporation $870.00 10/01/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation No dispute reported 06/30/2026 1017212603
Principal investigator 1 Genentech, Inc. $1,350.00 09/27/2023 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1040616104
Principal investigator 1 Genentech, Inc. $1,350.00 09/27/2023 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1040616119
Principal investigator 1 Seagen Inc. $1,389.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886007
Principal investigator 1 Seagen Inc. $460.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886149
Principal investigator 1 Seagen Inc. $295.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995886163
Principal investigator 1 Seagen Inc. $988.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886247
Principal investigator 1 Seagen Inc. $295.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995886321
Principal investigator 1 Seagen Inc. $164.50 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886367
Principal investigator 1 GlaxoSmithKline, LLC. $486.28 09/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173299
Principal investigator 1 Genentech, Inc. $511.00 09/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040608403
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 08/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173311
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 08/18/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173391
Principal investigator 1 Seagen Inc. $49.70 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885979
Principal investigator 1 Seagen Inc. $217.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886035
Principal investigator 1 Seagen Inc. $265.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886051
Principal investigator 1 Seagen Inc. $126.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886065
Principal investigator 1 Seagen Inc. $29.40 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886093
Principal investigator 1 Seagen Inc. $126.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886133
Principal investigator 1 Seagen Inc. $49.70 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886189
Principal investigator 1 Seagen Inc. $126.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886219
Principal investigator 1 Seagen Inc. $126.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886233
Principal investigator 1 Seagen Inc. $850.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886277
Principal investigator 1 Seagen Inc. $850.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886353
Principal investigator 1 Seagen Inc. $29.40 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886381
Principal investigator 1 Seagen Inc. $193.00 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886397
Principal investigator 1 Seagen Inc. $164.50 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886423
Principal investigator 1 Seagen Inc. $1,388.80 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886469
Principal investigator 1 Seagen Inc. $987.70 08/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886483
Principal investigator 1 GlaxoSmithKline, LLC. $305.00 08/10/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173337
Principal investigator 1 Genentech, Inc. $26,693.00 08/04/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607669
Principal investigator 1 Genentech, Inc. $114.00 07/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607257
Principal investigator 1 Genentech, Inc. $390.00 07/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607273
Principal investigator 1 Genentech, Inc. $114.00 07/21/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607175
Principal investigator 1 Genentech, Inc. $973.00 07/21/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607191
Principal investigator 1 AstraZeneca Pharmaceuticals LP $893.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 991130849
Principal investigator 1 AstraZeneca Pharmaceuticals LP $850.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 991132101
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,009.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991138227
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,655.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991140181
Principal investigator 1 Seagen Inc. $193.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885965
Principal investigator 1 Seagen Inc. $280.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885993
Principal investigator 1 Seagen Inc. $193.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886079
Principal investigator 1 Seagen Inc. $3,550.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886107
Principal investigator 1 Seagen Inc. $765.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886119
Principal investigator 1 Seagen Inc. $956.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995886203
Principal investigator 1 Seagen Inc. $126.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886291
Principal investigator 1 Seagen Inc. $126.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886411
Principal investigator 1 Seagen Inc. $164.50 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886437
Principal investigator 1 Seagen Inc. $126.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995886453
Principal investigator 1 Genentech, Inc. $1,500.00 07/14/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040607011
Principal investigator 1 GlaxoSmithKline, LLC. $915.00 07/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172823
Principal investigator 1 Veru Inc. $975.00 07/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1058357483
Principal investigator 1 Veru Inc. $10,000.00 06/16/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1058356851
Principal investigator 1 GlaxoSmithKline, LLC. $2,923.00 06/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173351
Principal investigator 1 Seagen Inc. $164.50 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885361
Principal investigator 1 Seagen Inc. $126.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885405
Principal investigator 1 Seagen Inc. $3,100.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885419
Principal investigator 1 Seagen Inc. $280.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885433
Principal investigator 1 Seagen Inc. $3,550.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885449
Principal investigator 1 Seagen Inc. $126.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885725
Principal investigator 1 Seagen Inc. $126.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885739
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 06/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172873
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 06/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173795
Principal investigator 1 GlaxoSmithKline, LLC. $305.00 05/18/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173783
Principal investigator 1 Seagen Inc. $987.70 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885231
Principal investigator 1 Seagen Inc. $3,482.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885245
Principal investigator 1 Seagen Inc. $295.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885259
Principal investigator 1 Seagen Inc. $193.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885303
Principal investigator 1 Seagen Inc. $1,388.80 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885318
Principal investigator 1 Seagen Inc. $3,875.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885333
Principal investigator 1 Seagen Inc. $164.50 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885347
Principal investigator 1 Seagen Inc. $295.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885565
Principal investigator 1 Seagen Inc. $295.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885577
Principal investigator 1 Seagen Inc. $3,482.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885591
Principal investigator 1 Seagen Inc. $987.70 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885605
Principal investigator 1 Genentech, Inc. $1,500.00 05/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040604761
Principal investigator 1 Genentech, Inc. $14,385.00 05/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040604859
Principal investigator 1 Seagen Inc. $265.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885099
Principal investigator 1 Seagen Inc. $280.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885113
Principal investigator 1 Seagen Inc. $1,388.80 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885129
Principal investigator 1 Seagen Inc. $765.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885143
Principal investigator 1 Seagen Inc. $164.50 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885159
Principal investigator 1 Seagen Inc. $987.70 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885173
Principal investigator 1 Seagen Inc. $193.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885189
Principal investigator 1 Seagen Inc. $3,490.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885203
Principal investigator 1 Seagen Inc. $126.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885217
Principal investigator 1 Seagen Inc. $193.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885551
Principal investigator 1 Seagen Inc. $956.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885621
Principal investigator 1 Seagen Inc. $280.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885637
Principal investigator 1 Seagen Inc. $265.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885665
Principal investigator 1 Seagen Inc. $193.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885695
Principal investigator 1 Seagen Inc. $987.70 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885709
Principal investigator 1 GlaxoSmithKline, LLC. $2,923.00 04/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173415
Principal investigator 1 GlaxoSmithKline, LLC. $1,703.00 04/12/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172811
Principal investigator 1 Genentech, Inc. $22,134.00 04/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040603997
Principal investigator 1 Genentech, Inc. $1,500.00 03/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040606609
Principal investigator 1 Genentech, Inc. $1,500.00 03/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040606625
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 03/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173427
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 03/22/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173771
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,490.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991133215
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 03/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172835
Principal investigator 1 GlaxoSmithKline, LLC. $110,000.00 03/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173759
Principal investigator 1 Seagen Inc. $164.50 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885467
Principal investigator 1 Seagen Inc. $2,400.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885481
Principal investigator 1 Seagen Inc. $193.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885495
Principal investigator 1 Seagen Inc. $3,482.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885509
Principal investigator 1 Seagen Inc. $411.60 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885523
Principal investigator 1 Seagen Inc. $4,850.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885537
Principal investigator 1 Seagen Inc. $193.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885791
Principal investigator 1 Seagen Inc. $164.50 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995885803
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,181.00 03/09/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A phase II multicenter open label two cohort non comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant hormone receptor HR positive HER2 negative advanced breast cancer aBC who have progressed on or after CDK 4 6 inhibitor treatment No dispute reported 06/30/2026 1017240113
Principal investigator 1 Genentech, Inc. $170.00 03/08/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1040606491
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,815.33 03/03/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 991130491
Principal investigator 1 Eli Lilly and Company $15,180.00 02/21/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK NODE POSITIVE EARLY STAGE HORMONE RECEPTOR POSITIVE HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 1038156145
Principal investigator 1 Eli Lilly and Company $0.03 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK NODE POSITIVE EARLY STAGE HORMONE RECEPTOR POSITIVE HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 1038144647
Principal investigator 1 GlaxoSmithKline, LLC. $31,493.00 02/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172847
Principal investigator 1 Seagen Inc. $3,875.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883977
Principal investigator 1 Seagen Inc. $295.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995884007
Principal investigator 1 Seagen Inc. $295.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885753
Principal investigator 1 Seagen Inc. $295.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885767
Principal investigator 1 Seagen Inc. $295.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995885781
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 02/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172861
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 02/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173405
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 01/31/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006172885
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 01/31/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1006173323
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,770.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 991125865
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,287.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991133001
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,550.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 991135501
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,903.55 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991136281
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,124.40 01/15/2023 Non-covered Recipient Entity
CANCER CARE NETWORK OF SOUTH TEXAS P.A.
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991139137
Principal investigator 1 Eli Lilly and Company $13,586.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK NODE POSITIVE EARLY STAGE HORMONE RECEPTOR POSITIVE HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 1038135337
Principal investigator 1 Eli Lilly and Company $3,824.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK NODE-POSITIVE HR+ HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1038139027
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,397.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
A phase II multicenter open label two cohort non comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant hormone receptor HR positive HER2 negative advanced breast cancer aBC who have progressed on or after CDK 4 6 inhibitor treatment No dispute reported 06/30/2026 1017210869
Principal investigator 1 Seagen Inc. $765.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883791
Principal investigator 1 Seagen Inc. $2,400.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883803
Principal investigator 1 Seagen Inc. $123.20 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883817
Principal investigator 1 Seagen Inc. $4,850.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883847
Principal investigator 1 Seagen Inc. $67.20 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883875
Principal investigator 1 Seagen Inc. $48.30 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883889
Principal investigator 1 Seagen Inc. $411.60 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883903
Principal investigator 1 Seagen Inc. $126.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883919
Principal investigator 1 Seagen Inc. $29.40 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883933
Principal investigator 1 Seagen Inc. $49.70 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883949
Principal investigator 1 Seagen Inc. $164.50 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 995883963
Principal investigator 1 Seagen Inc. $956.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995884361
Principal investigator 1 AstraZeneca Pharmaceuticals LP $70,909.43 01/11/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991134633
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,990.80 01/11/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 991136921
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 01/06/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 991128271
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,790.00 01/01/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation No dispute reported 06/30/2026 1017188767
Principal investigator 2 Novartis Pharmaceuticals Corporation $2,750.00 01/01/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation No dispute reported 06/30/2026 1017210475